TrialClinical and experimental nephrology2021

Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.

Kazuhiko Tsuruya et al.PubMed ↗Publisher ↗

No numbers read from the abstract.